This finding may potentially broaden the scope of application of PARP inhibitors, and suggests that targeting the H19/ILF2/BRCA1 axis may potentially serve as a valuable combination therapeutic approach for breast cancer. This evidence concerns the gene BRCA1 and breast carcinoma.